Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromocriptine plus medroxyprogesterone for ovarian endometrioma
IRCT20140802018655N6Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in endometrioma and endometriosis comparing Medroxyprogesterone + bromocriptine with Medroxyprogesterone + placebo (2 arms). Primary endpoints: Endometrioma size, Dysmenorrhea and 1 more. Started Dec 2018; status: completed.
02
Drugs
bromocriptinemedroxyprogesterone acetate
03
Conditions
endometriomaendometriosis
Beyond the preview
Go deeper on IRCT20140802018655N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140802018655N6.